GSK lawyer: CMA paroxetine decision was “overreach”

The UK’s antitrust watchdog was wrong to paint patent settlements between GlaxoSmithKline and two generic drugmakers as an illegal pay-for-delay scheme, counsel to the pharmaceutical company told the Competition Appeal Tribunal today.

Get unlimited access to all Global Competition Review content